Welcome to our dedicated page for SenesTech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on SenesTech stock.
SenesTech, Inc. (Nasdaq: SNES) is a pioneering biotechnology company based in the United States, specializing in the development of innovative fertility control solutions for managing animal pest populations. SenesTech is dedicated to improving global health through humane pest control methods, reducing the reliance on traditional lethal techniques.
The company’s flagship product, ContraPest®, is the first and only U.S. EPA-registered contraceptive for male and female rats. As a highly palatable liquid, ContraPest disrupts the reproductive cycle of Norway and roof rats, effectively reducing their populations. The product is dispensed inside tamper-resistant bait stations to minimize risks to non-target species and ensure the safety of handlers. ContraPest can be integrated into existing pest management programs or used as a standalone solution.
SenesTech's latest innovation, Evolve™, an EPA-designated minimum-risk contraceptive for rats, showcases the company's commitment to sustainable and humane pest control solutions. Evolve, available in a soft bait format, was launched in early 2024 and has already seen significant market acceptance. Its rapid adoption by distributors and end customers underscores its effectiveness in managing rodent populations by targeting their reproductive capabilities.
The company has expanded its reach by establishing distribution agreements with international partners, such as Agro Technic in Singapore, Evicom in Australia and New Zealand, and Q-chem in The Netherlands. These partnerships are pivotal in introducing SenesTech's fertility control solutions to new markets and enhancing global pest management strategies.
In addition to its product innovations, SenesTech has been recognized for its commercial achievements. The company was recently accepted as a vendor for Ace Hardware, allowing over 4,500 stores to order directly from SenesTech. Furthermore, SenesTech has launched a dedicated online store on Amazon, providing consumers and professionals with easy access to Evolve.
Financially, SenesTech reported record quarterly revenues in early 2024, driven by the rapid adoption of Evolve. The company's strategic initiatives, including the development of a contraceptive product for mice and operational efficiencies, are expected to sustain this growth trajectory.
SenesTech's mission is clear: to promote clean cities, efficient businesses, and happy households by providing humane, effective, and sustainable pest control solutions. For more information, visit SenesTech and ContraPest Store.
SenesTech, Inc. (SNES) has announced the EPA approval and launch of its Elevate Bait System with ContraPest, targeting rat infestations in above-ground locations. This innovative bait system allows for easy deployment in settings such as barns and granaries, significantly reducing servicing time with its design for quick bottle replacement. With ContraPest's proven ability to reduce rat populations by 60-90%, the company expects enhanced sales, particularly in agriculture, as state registrations progress for a mid-April shipping date.
SenesTech, Inc. (NASDAQ: SNES) has announced the deployment of its ContraPest® product at a 2,500-bed medium security correctional facility, marking a significant first for pest control in major correctional settings.
ContraPest, a non-lethal rodent birth control solution, is designed to tackle complex challenges in correctional environments, achieving population reduction in rats by at least 94%. The product is capable of being deployed in various locations and seeks to expand within institutional settings. CEO Ken Siegel noted the importance of this advancement for pest management professionals.
SenesTech, Inc. (NASDAQ: SNES) announced the deployment of its rodent fertility control product, ContraPest®, at Safari West Wildlife Preserve in California. This initiative is part of a broader eco-friendly pest management strategy, crucial for controlling rat populations that can rapidly reproduce in safe environments. ContraPest offers a non-lethal solution that has proven to reduce rat populations by at least 94%. The product is now increasingly being adopted in zoos and sanctuaries across the U.S., with expectations of continued growth in this market.
SenesTech (NASDAQ: SNES) announced that Columbus, Ohio has integrated ContraPest® into its pest management program, joining other cities like San Francisco and Washington D.C. This environmentally friendly solution has achieved up to a 94% reduction in urban rat populations. Columbus enhances its free residential pest management services with ContraPest, focusing on eco-friendly approaches. CEO Ken Siegel noted the growing acceptance of fertility control methods in pest management, especially after California's ban on certain rodenticides. The company aims for further expansion into other municipalities.
SenesTech (SNES) announced that Los Angeles County will require fertility control in pest management proposals for 2022. This mandate highlights the importance of SenesTech's product, ContraPest®, the only EPA registered rodent fertility control solution. ContraPest® can reduce rat populations by up to 94% when integrated into pest management programs. Following California's legislation banning certain rodenticides, demand for humane pest control alternatives is expected to grow, with other municipalities adopting ContraPest® as well.
SenesTech, a leader in animal pest management through fertility control, will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. The company will host a webcasted Fireside Chat on December 13 at 11:00am ET, discussing its 2022 vision. Investors can view the webcast on the company's website or via a specific link. Additionally, 1x1 virtual meetings with management can be arranged through Lytham Partners. SenesTech focuses on rodent fertility control, aiming to reduce pest populations and promote a healthier environment.
SenesTech (NASDAQ: SNES) reported that Q3 2021 revenues exceeded $183,000, more than doubling from $77,000 in Q3 2020. Year-to-date revenues also more than doubled, driven by growth in agribusiness, municipalities, and direct-to-consumer markets. The company added around 350 new customers, with California sales accounting for nearly 30% of total sales. Despite revenue growth, Q3 net loss widened to $(2.3) million from $(1.9) million in Q3 2020. As of September, the company had $11.1 million in cash to support further growth initiatives.
SenesTech, Inc. (NASDAQ: SNES) will report its financial results for Q3 2021 after market close on November 10, 2021. A conference call is scheduled for the same day at 5:00 pm ET to discuss the results. SenesTech focuses on managing pest populations through its proprietary fertility control technology, ContraPest®, which is the first EPA registered rodent contraceptive. This initiative aims to significantly reduce rodent populations and promote a healthier environment.
SenesTech (NASDAQ: SNES) has seen municipalities across the U.S. increasingly adopt its rat contraceptive, ContraPest®, with Newton, Massachusetts, now joining cities like Washington DC and San Francisco. ContraPest® is the only EPA-approved rat birth control, demonstrating over 94% efficacy in reducing rat populations. Sales revenues for ContraPest® soared over 100% in 2021, primarily driven by California's implementation of rodenticide restrictions. This innovative solution addresses the growing rat problem exacerbated by the pandemic, aiming for sustainable pest control without harmful impacts.
SenesTech, Inc. (NASDAQ: SNES) has announced its participation in the Lytham Partners Fall 2021 Investor Conference on October 7, 2021 at 3:30 PM ET. The event will be accessible via a webcast on the company's website, with an archived replay available post-event. Management will also hold virtual one-on-one meetings during the conference from October 5 to 7. As a leader in fertility control technology for pest management, SenesTech aims to promote a healthier environment through its proprietary product, ContraPest, the first U.S. EPA registered rodent contraceptive.
FAQ
What is the current stock price of SenesTech (SNES)?
What is the market cap of SenesTech (SNES)?
What is SenesTech, Inc.?
What products does SenesTech offer?
How does ContraPest work?
What are the benefits of using Evolve?
Who are SenesTech’s distribution partners?
Where can I purchase SenesTech products?
What is the financial outlook for SenesTech?
What makes SenesTech's products unique?
Are SenesTech’s products safe for non-target species?
What is SenesTech's mission?
